DOCSLIB.ORG

Influence of the F8-Adrenergic Receptor Concentration on Functional Coupling to the Adenylate Cyclase System

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Influence of the F8-Adrenergic Receptor Concentration on Functional Coupling to the Adenylate Cyclase System Proc. Natl. Acad. Sci. USA Vol. 81, pp. 4637-4641, August 1984 Biochemistry Influence of the f8-adrenergic receptor concentration on functional coupling to the adenylate cyclase system (receptor number/functional heterogeneity/agonist-N-ethylmaleimide sensitivity) YVONNE SEVERNE, DIRK COPPENS, SERGE BOTTARI, MICHELE RIVIEREt, RAPHAEL KRAMtt, AND GEORGES VAUQUELIN *Laboratorium Chemie der Proteinen, Instituut Moleculaire Biologie, Vrije Universiteit Brussel, 65 Paardenstraat, 1640 St. Genesius-Rode, Belgium; and tLaboratoire de Biologie Cellulaire et Moleculaire du Developpement, Departement de Biologie Moleculaire, Universite Libre de Bruxelles, 67 Rue des Chevaux, 1640 Rhode St. Genese, Belgium Communicated by J. Brachet, April 26, 1984 ABSTRACT Only part of the ,B-adrenergic receptors can dence for the view that the action of both Mg2' and reagent undergo functional coupling to the adenylate cyclase regula- requires the coupling between the receptor and the guanine tory unit. This receptor subpopulation shows an increased af- nucleotide-binding regulatory component of the adenylate finity for agonists in the presence of Mg2' and undergoes rap- cyclase system, designated Ns (8, 12). In this context, cur- id "inactivation" (locking-in of the agonist) by the alkylating rent models concerning the MalNEt action mechanism are reagent N-ethylmaleimide in the presence of agonists. Several based on the fact that coupling of the agonist-bound /3-adren- experimental conditions, known to modify the total receptor ergic receptor to Ns is accompanied by the exposure of sulf- concentration without alteration of the other components of hydryl groups, probably at the surface of Ns itself (unpub- the acenylate cyclase system, do not affect the percentage of lished data; ref. 10). Alkylation of these groups by MalNEt receptors that can undergo functional coupling: (i) homolo- results in the freezing of the receptors in an active, slow ago- gous regulation of B13 receptors in rat brain by noradrenaline nist-dissociating conformation (i.e., locking-in of the ago- (through antidepressive drug or reserpine injections); (it) up- nist) and, hence, in their apparent inactivation (9, 10). and down-regulation of the 182 receptors in Friend erythroleu- To investigate the possible basis for the restriction in re- kemia cells by, respectively, sodium butyrate and cinnarizine ceptor-Ns coupling, we have tested whether various factors treatment; and (iiW) dithiothreitol-mediated inactivation of re- known to alter the total receptor number could also alter the ceptors in turkey erythrocytes, Friend erythroleukemia cells, proportion of coupling-prone receptors. Using the agonist/ and rat brain. Our findings argue against a stoichiometric lim- MalNEt reaction, we show here that changes in the total re- itation in the number of regulatory components, genetically ceptor number by various factors (i.e., chemical inactiva- different receptor subpopulations, bound guanine nucleotides, tion, homologous hormonal regulation, and butyrate and cin- or reduced accessibility of part of the receptors to the agonists narizine treatment) do not necessarily imply an alteration of as the cause for functional receptor heterogeneity. Differences the Ns-coupled receptor fraction. Our data suggest that the in either the receptor conformation or its membrane microen- limited receptor-Ns coupling is probably related to limita- vironment are more plausible explanations. tions in the membrane or receptor structure. Several recent studies have shed light on marked structural MATERIALS AND METHODS and functional differences between /-adrenergic agonists and antagonists in their interaction with their receptors (1- Materials. The following were obtained as kind gifts: (-)- 7). In particular, the receptors behave as a homogeneous isoproterenol bitartrate from Sterling Winthrop; fenoterol population of sites with regard to antagonist binding, but two hydrobromide from Boehringer-Ingelheim; practolol hydro- subpopulations can be discriminated for agonist binding. chloride from ICI; (+)-alprenolol hydrochloride, phentol- This has been established by two types of observations. amine hydrochloride, desipramine, and reserpine from First, magnesium ions cause an increase in agonist but not in CIBA-Geigy; doxepin from Pfizer; mianserin from Orga- antagonist affinity for binding to a well-defined proportion of non; pargyline from Abbott; and nisoxetine from Eli Lilly. the 8-adrenergic receptors in several tissues (5, 6). Second, Nialamide, MalNEt, and dithiothreitol were purchased from agonist but not antagonist binding causes a conformational Sigma. GTP and GMP were from Boehringer Mannheim. modification of only part of the B3-adrenergic receptors. This (-)-[3H]Dihydroalprenolol hydrochloride ([3H]H2Alp, 91 conformational modification can be monitored by the ability Ci/mmol; 1 Ci = 37 GBq) was obtained from New England of a combination of agonist and the group-specific reagent Nuclear. [3H]CGP 12177 (42 Ci/mmol) was from Amersham. N-ethylmaleimide (MalNEt) to impair subsequent radioli- All other chemicals were of analytical grade. gand binding (7-10). Source and Preparation of Membranes. Turkey erythro- Interestingly, both Mg2+ and MalNEt affect the same re- cyte membranes were prepared as described (7). ceptor subpopulation (unpublished data; ref. 8). Moreover, Male Wistar rats (-250 g) underwent either 14 daily intra- the basis of receptor heterogeneity is functional rather than peritoneal injections with saline solutions of antidepressant pharmacological. Experiments on turkey erythrocyte mem- drugs (i.e., desipramine, doxepin, nialamide, nisoxetine, and branes, human adipose cell membranes (,81-adrenergic re- mianserin at 10 mg/kg and pargyline at 25 mg/kg) or 4 daily ceptors), and S49 lymphoma cell membranes (132-adrenergic injections with a reserpine solution at 2.5 mg/kg; they were receptors) have shown that the agonist/MalNEt-sensitive then decapitated. All subsequent steps were performed at and -resistant receptors have the same pharmacological 4°C. The cerebral cortex was homogenized in 10 volumes of specificity (7, 8, 11). In contrast, there is now ample evi- 10 mM Tris-HCl, pH 7.4/0.25 M sucrose in an Ultraturax The publication costs of this article were defrayed in part by page charge Abbreviations: MalNEt, N-ethylmaleimide; [3H]H2Alp, (-)-[3H]di- payment. This article must therefore be hereby marked "advertisement" hydroalprenolol. in accordance with 18 U.S.C. §1734 solely to indicate this fact. tDeceased on May 25, 1983. 4637 Downloaded by guest on September 29, 2021 4638 Biochemistry: Severne et al. Proc. NatL Acad Sci. USA 81 (1984) homogenizer and subsequently in a glass/Teflon homogeniz- er (five strokes). The homogenate was centrifuged subse- 100i quently at 900, 10,000, and 40,000 x g for 15 min. The final pellet of cortical membranes was retained. 4-4 Friend erythroleukemia cell culture and membrane prepa- C ration are described in ref. 13. Receptor induction was ob- tained by incubation of the culture with 2 mM sodium buty- =n 050 rate for 24 hr. Incubation with 10 ,M cinnarizine lasted 24 hr. All membrane preparations were suspended in 10 mM 0 Tris HCl, pH 7.4, 10% (vol/vol) glycerol and stored in liquid nitrogen at a protein concentration of -10 mg/ml. Protein concentrations were determined according to Lowry et al. 0 5 1*0 15 20 (14). Preincubation time, min Membrane Pretreatments. Membranes (1-4 mg of protein per ml) were preincubated for 10 min at 30'C in 75 mM FIG. 1. Isoproterenol/MalNEt-mediated decrease in the 18-ad- Tris HCl, pH 7.4/25 mM MgCl2 containing 0.5 AuM (-)-iso- renergic receptor number in function of the preincubation time. Tur- proterenol/0.2 mM MalNEt in a final volume of 0.5 ml or 1 key erythrocyte membranes (A), rat brain membranes (U), and ml (for rat brain membranes). Preincubations were terminat- Friend erythroleukemia cell membranes (A) were pretreated at 30TC ed as follows: turkey erythrocytes and rat brain, centrifuga- with buffer only (for control binding) or with 0.5 AtM isoprotere- tion (2 min at 12,000 rpm in an Eppendorf centrifuge at room nol/0.2 mM MalNEt for the indicated periods of time (abscissa), and of the membranes in 1 ml of after which the membranes were washed and assayed for [3H]H2Alp temperature) resuspension binding. For all of the membrane preparations, control binding re- fresh buffer (three times); Friend erythroleukemia cells, cen- mained constant throughout the duration of preincubation. trifugation as above but in the presence of 4% (vol/vol) poly- ethylene glycol 6000 (final concentration). Polyethylene gly- col 6000 allowed fast and quantitative precipitation of the dioligand [3H]CGP 12177 (17) reached comparable plateau membranes and affected neither [3H]H2Alp binding nor re- values-i.e., 60%, 40%, and 31%. Pretreatment of the three ceptor-Ns coupling. Preincubation of various membranes types of membranes for 15 min with 1 ttM (-)-isoprotere- with 5 mM dithiothreitol was performed as described (15). nol/1 mM GMP, known to remove tightly bound guanine nu- Radioligand Binding. Binding of [3H]H2Alp and [3H]CGP cleotides (18), did not increase the subsequent agonist/Mal- 12177 to the membrane preparations was assayed by filtra- NEt-mediated decline in [3H]H2Alp binding either; plateau tion on glass fiber filters. Membrane protein (0.75-2 mg/ml) values were 71%, 39%, and 42%. was incubated with the indicated concentrations of radiolig- Repeated intraperitoneal injections of antidepressive and for 10 min at 30°C
Load more

Recommended publications
  • 2D6 Substrates 2D6 Inhibitors 2D6 Inducers
    Physician Guidelines: Drugs Metabolized by Cytochrome P450’s 1 2D6 Substrates Acetaminophen Captopril Dextroamphetamine Fluphenazine Methoxyphenamine Paroxetine Tacrine Ajmaline Carteolol Dextromethorphan Fluvoxamine Metoclopramide Perhexiline Tamoxifen Alprenolol Carvedilol Diazinon Galantamine Metoprolol Perphenazine Tamsulosin Amiflamine Cevimeline Dihydrocodeine Guanoxan Mexiletine Phenacetin Thioridazine Amitriptyline Chloropromazine Diltiazem Haloperidol Mianserin Phenformin Timolol Amphetamine Chlorpheniramine Diprafenone Hydrocodone Minaprine Procainamide Tolterodine Amprenavir Chlorpyrifos Dolasetron Ibogaine Mirtazapine Promethazine Tradodone Aprindine Cinnarizine Donepezil Iloperidone Nefazodone Propafenone Tramadol Aripiprazole Citalopram Doxepin Imipramine Nifedipine Propranolol Trimipramine Atomoxetine Clomipramine Encainide Indoramin Nisoldipine Quanoxan Tropisetron Benztropine Clozapine Ethylmorphine Lidocaine Norcodeine Quetiapine Venlafaxine Bisoprolol Codeine Ezlopitant Loratidine Nortriptyline Ranitidine Verapamil Brofaramine Debrisoquine Flecainide Maprotline olanzapine Remoxipride Zotepine Bufuralol Delavirdine Flunarizine Mequitazine Ondansetron Risperidone Zuclopenthixol Bunitrolol Desipramine Fluoxetine Methadone Oxycodone Sertraline Butylamphetamine Dexfenfluramine Fluperlapine Methamphetamine Parathion Sparteine 2D6 Inhibitors Ajmaline Chlorpromazine Diphenhydramine Indinavir Mibefradil Pimozide Terfenadine Amiodarone Cimetidine Doxorubicin Lasoprazole Moclobemide Quinidine Thioridazine Amitriptyline Cisapride
    [Show full text]
  • The In¯Uence of Medication on Erectile Function
    International Journal of Impotence Research (1997) 9, 17±26 ß 1997 Stockton Press All rights reserved 0955-9930/97 $12.00 The in¯uence of medication on erectile function W Meinhardt1, RF Kropman2, P Vermeij3, AAB Lycklama aÁ Nijeholt4 and J Zwartendijk4 1Department of Urology, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands; 2Department of Urology, Leyenburg Hospital, Leyweg 275, 2545 CH The Hague, The Netherlands; 3Pharmacy; and 4Department of Urology, Leiden University Hospital, P.O. Box 9600, 2300 RC Leiden, The Netherlands Keywords: impotence; side-effect; antipsychotic; antihypertensive; physiology; erectile function Introduction stopped their antihypertensive treatment over a ®ve year period, because of side-effects on sexual function.5 In the drug registration procedures sexual Several physiological mechanisms are involved in function is not a major issue. This means that erectile function. A negative in¯uence of prescrip- knowledge of the problem is mainly dependent on tion-drugs on these mechanisms will not always case reports and the lists from side effect registries.6±8 come to the attention of the clinician, whereas a Another way of looking at the problem is drug causing priapism will rarely escape the atten- combining available data on mechanisms of action tion. of drugs with the knowledge of the physiological When erectile function is in¯uenced in a negative mechanisms involved in erectile function. The way compensation may occur. For example, age- advantage of this approach is that remedies may related penile sensory disorders may be compen- evolve from it. sated for by extra stimulation.1 Diminished in¯ux of In this paper we will discuss the subject in the blood will lead to a slower onset of the erection, but following order: may be accepted.
    [Show full text]
  • M100907, a Serotonin 5-HT2A Receptor Antagonist and Putative Antipsychotic, Blocks Dizocilpine-Induced Prepulse Inhibition Defic
    M100907, a Serotonin 5-HT2A Receptor Antagonist and Putative Antipsychotic, Blocks Dizocilpine-Induced Prepulse Inhibition Deficits in Sprague–Dawley and Wistar Rats Geoffrey B. Varty, Ph.D., Vaishali P. Bakshi, Ph.D., and Mark A. Geyer, Ph.D. a In a recent study using Wistar rats, the serotonergic 5-HT2 1 receptor agonist cirazoline disrupts PPI. As risperidone a receptor antagonists ketanserin and risperidone reduced the and M100907 have affinity at the 1 receptor, a final study disruptive effects of the noncompetitive N-methyl-D- examined whether M100907 would block the effects of aspartate (NMDA) antagonist dizocilpine on prepulse cirazoline on PPI. Risperidone partially, but inhibition (PPI), suggesting that there is an interaction nonsignificantly, reduced the effects of dizocilpine in Wistar between serotonin and glutamate in the modulation of PPI. rats, although this effect was smaller than previously In contrast, studies using the noncompetitive NMDA reported. Consistent with previous studies, risperidone did antagonist phencyclidine (PCP) in Sprague–Dawley rats not alter the effects of dizocilpine in Sprague–Dawley rats. found no effect with 5-HT2 antagonists. To test the hypothesis Most importantly, M100907 pretreatment fully blocked the that strain differences might explain the discrepancy in effect of dizocilpine in both strains; whereas SDZ SER 082 these findings, risperidone was tested for its ability to had no effect. M100907 had no influence on PPI by itself reduce the PPI-disruptive effects of dizocilpine in Wistar and did not reduce the effects of cirazoline on PPI. These and Sprague–Dawley rats. Furthermore, to determine studies confirm the suggestion that serotonin and glutamate which serotonergic receptor subtype may mediate this effect, interact in modulating PPI and indicate that the 5-HT2A the 5-HT2A receptor antagonist M100907 (formerly MDL receptor subtype mediates this interaction.
    [Show full text]
  • Properties and Units in Clinical Pharmacology and Toxicology
    Pure Appl. Chem., Vol. 72, No. 3, pp. 479–552, 2000. © 2000 IUPAC INTERNATIONAL FEDERATION OF CLINICAL CHEMISTRY AND LABORATORY MEDICINE SCIENTIFIC DIVISION COMMITTEE ON NOMENCLATURE, PROPERTIES, AND UNITS (C-NPU)# and INTERNATIONAL UNION OF PURE AND APPLIED CHEMISTRY CHEMISTRY AND HUMAN HEALTH DIVISION CLINICAL CHEMISTRY SECTION COMMISSION ON NOMENCLATURE, PROPERTIES, AND UNITS (C-NPU)§ PROPERTIES AND UNITS IN THE CLINICAL LABORATORY SCIENCES PART XII. PROPERTIES AND UNITS IN CLINICAL PHARMACOLOGY AND TOXICOLOGY (Technical Report) (IFCC–IUPAC 1999) Prepared for publication by HENRIK OLESEN1, DAVID COWAN2, RAFAEL DE LA TORRE3 , IVAN BRUUNSHUUS1, MORTEN ROHDE1, and DESMOND KENNY4 1Office of Laboratory Informatics, Copenhagen University Hospital (Rigshospitalet), Copenhagen, Denmark; 2Drug Control Centre, London University, King’s College, London, UK; 3IMIM, Dr. Aiguader 80, Barcelona, Spain; 4Dept. of Clinical Biochemistry, Our Lady’s Hospital for Sick Children, Crumlin, Dublin 12, Ireland #§The combined Memberships of the Committee and the Commission (C-NPU) during the preparation of this report (1994–1996) were as follows: Chairman: H. Olesen (Denmark, 1989–1995); D. Kenny (Ireland, 1996); Members: X. Fuentes-Arderiu (Spain, 1991–1997); J. G. Hill (Canada, 1987–1997); D. Kenny (Ireland, 1994–1997); H. Olesen (Denmark, 1985–1995); P. L. Storring (UK, 1989–1995); P. Soares de Araujo (Brazil, 1994–1997); R. Dybkær (Denmark, 1996–1997); C. McDonald (USA, 1996–1997). Please forward comments to: H. Olesen, Office of Laboratory Informatics 76-6-1, Copenhagen University Hospital (Rigshospitalet), 9 Blegdamsvej, DK-2100 Copenhagen, Denmark. E-mail: [email protected] Republication or reproduction of this report or its storage and/or dissemination by electronic means is permitted without the need for formal IUPAC permission on condition that an acknowledgment, with full reference to the source, along with use of the copyright symbol ©, the name IUPAC, and the year of publication, are prominently visible.
    [Show full text]
  • Covalent Agonists for Studying G Protein-Coupled Receptor Activation
    Covalent agonists for studying G protein-coupled receptor activation Dietmar Weicherta, Andrew C. Kruseb, Aashish Manglikb, Christine Hillera, Cheng Zhangb, Harald Hübnera, Brian K. Kobilkab,1, and Peter Gmeinera,1 aDepartment of Chemistry and Pharmacy, Friedrich Alexander University, 91052 Erlangen, Germany; and bDepartment of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA 94305 Contributed by Brian K. Kobilka, June 6, 2014 (sent for review April 21, 2014) Structural studies on G protein-coupled receptors (GPCRs) provide Disulfide-based cross-linking approaches (17, 18) offer important insights into the architecture and function of these the advantage that the covalent binding of disulfide-containing important drug targets. However, the crystallization of GPCRs in compounds is chemoselective for cysteine and enforced by the active states is particularly challenging, requiring the formation of affinity of the ligand-pharmacophore rather than by the elec- stable and conformationally homogeneous ligand-receptor com- trophilicity of the cross-linking function (19). We refer to the plexes. Native hormones, neurotransmitters, and synthetic ago- described ligands as covalent rather than irreversible agonists nists that bind with low affinity are ineffective at stabilizing an because cleavage may be promoted by reducing agents and the active state for crystallogenesis. To promote structural studies on disulfide transfer process is a reversible chemical reaction the pharmacologically highly relevant class
    [Show full text]
  • The Adrenergic Control of Lower Esophageal Sphincter Function: an EXPERIMENTAL MODEL of DENERVATION SUPERSENSITIVITY
    The Adrenergic Control of Lower Esophageal Sphincter Function: AN EXPERIMENTAL MODEL OF DENERVATION SUPERSENSITIVITY Anthony J. DiMarino, Sidney Cohen J Clin Invest. 1973;52(9):2264-2271. https://doi.org/10.1172/JCI107413. To evaluate the adrenergic regulation of lower esophageal sphincter (LES) function, LES pressure, LES relaxation during swallowing, and blood pressure were measured in the anesthetized opossum, Didelphis virginiana, during intravenous administration of alpha and beta adrenergic agonists and antagonists. Studies were done in controls and animals adrenergically denervated with 6-hydroxydopamine. Alpha adrenergic agonists (norepinephrine, phenylephrine) increased LES pressure and blood pressure, whereas a beta adrenergic agonist (isoproterenol) decreased both pressures. Alpha adrenergic antagonism (phentolamine) reduced basal LES pressure by 38.3±3.8% (mean ±SEM) (P < 0.001). Beta adrenergic antagonism (propranolol) had no significant effect on either basal LES pressure or percent of LES relaxation with swallowing. After adrenergic denervation with 6-hydroxydopamine, basal LES pressure was reduced by 22.5±5.3% (P < 0.025) but LES relaxation during swallowing was unaltered. In denervated animals, both LES pressure and blood pressure dose response curves showed characteristics of denervation supersensitivity to alpha but not to beta adrenergic agonists. These studies suggest: (a) a significant portion of basal LES pressure is dependent upon alpha adrenergic stimulation; (b) LES relaxation during swallowing is not an adrenergically mediated response; c( ) the LES pressure response to alpha adrenergic agonists after 6-hydroxydopamine may serve as a model of denervation supersensitivity in the gastrointestinal tract. Find the latest version: https://jci.me/107413/pdf The Adrenergic Control of Lower Esophageal Sphincter Function AN EXPERIMENTAL MODEL OF DENERVATION SUPERSENSITIVITY ANTHoNY J.
    [Show full text]
  • Pharmacological Approach to Sleep Disturbances in Autism Spectrum Disorders with Psychiatric Comorbidities: a Literature Review
    medical sciences Review Pharmacological Approach to Sleep Disturbances in Autism Spectrum Disorders with Psychiatric Comorbidities: A Literature Review Sachin Relia 1,* and Vijayabharathi Ekambaram 2,* 1 Department of Psychiatry, University of Tennessee Health Sciences Center, 920, Madison Avenue, Suite 200, Memphis, TN 38105, USA 2 Department of Psychiatry, University of Oklahoma Health Sciences Center, 920, Stanton L Young Blvd, Oklahoma City, OK 73104, USA * Correspondence: [email protected] (S.R.); [email protected] (V.E.); Tel.: +1-901-448-4266 (S.R.); +1-405-271-5251 (V.E.); Fax: +1-901-297-6337 (S.R.); +1-405-271-3808 (V.E.) Received: 15 August 2018; Accepted: 17 October 2018; Published: 25 October 2018 Abstract: Autism is a developmental disability that can cause significant emotional, social and behavioral dysfunction. Sleep disorders co-occur in approximately half of the patients with autism spectrum disorder (ASD). Sleep problems in individuals with ASD have also been associated with poor social interaction, increased stereotypy, problems in communication, and overall autistic behavior. Behavioral interventions are considered a primary modality of treatment. There is limited evidence for psychopharmacological treatments in autism; however, these are frequently prescribed. Melatonin, antipsychotics, antidepressants, and α agonists have generally been used with melatonin, having a relatively large body of evidence. Further research and information are needed to guide and individualize treatment for this population group. Keywords: autism spectrum disorder; sleep disorders in ASD; medications for sleep disorders in ASD; comorbidities in ASD 1. Introduction Autism is a developmental disability that can cause significant emotional, social, and behavioral dysfunction. According to the Diagnostic and Statistical Manual (DSM-V) classification [1], autism spectrum disorder (ASD) is characterized by persistent deficits in domains of social communication, social interaction, restricted and repetitive patterns of behavior, interests, or activities.
    [Show full text]
  • Drug-Facilitated Sexual Assault Panel, Blood
    DRUG-FACILITATED SEXUAL ASSAULT PANEL, BLOOD Blood Specimens (Order Code 70500) Alcohols Analgesics, cont. Anticonvulsants, cont. Antihistamines, cont. Ethanol Phenylbutazone Phenytoin Cyclizine Amphetamines Piroxicam Pregabalin Diphenhydramine Amphetamine Salicylic Acid* Primidone Doxylamine BDB Sulindac* Topiramate Fexofenadine Benzphetamine Tapentadol Zonisamide Guaifenesin Ephedrine Tizanidine Antidepressants Hydroxyzine MDA Tolmetin Amitriptyline Loratadine MDMA Tramadol Amoxapine Oxymetazoline* Mescaline* Anesthetics Bupropion Pyrilamine Methcathinone Benzocaine Citalopram Tetrahydrozoline Methamphetamine Bupivacaine Clomipramine Triprolidine Phentermine Etomidate Desipramine Antipsychotics PMA Ketamine Desmethylclomipramine 9-hydroxyrisperidone Phenylpropanolamine Lidocaine Dosulepin Aripiprazole Pseudoephedrine Mepivacaine Doxepin Buspirone Analgesics Methoxetamine Duloxetine Chlorpromazine Acetaminophen Midazolam Fluoxetine Clozapine Baclofen Norketamine Fluvoxamine Fluphenazine Buprenorphine Pramoxine* Imipramine Haloperidol Carisoprodol Procaine 1,3-chlorophenylpiperazine (mCPP) Mesoridazine Cyclobenzaprine Rocuronium Mianserin* Norclozapine Diclofenac Ropivacaine Mirtazapine Olanzapine Etodolac Antibiotics Nefazodone Perphenazine Fenoprofen Azithromycin* Nordoxepin Pimozide Hydroxychloroquine Chloramphenicol* Norfluoxetine Prochlorperazine Ibuprofen Ciprofloxacin* Norsertraline Quetiapine Ketoprofen Clindamycin* Nortriptyline Risperidone Ketorolac Erythromycin* Norvenlafaxine Thioridazine Meclofenamic Acid* Levofloxacin* Paroxetine
    [Show full text]
  • Hallucinogens: an Update
    National Institute on Drug Abuse RESEARCH MONOGRAPH SERIES Hallucinogens: An Update 146 U.S. Department of Health and Human Services • Public Health Service • National Institutes of Health Hallucinogens: An Update Editors: Geraline C. Lin, Ph.D. National Institute on Drug Abuse Richard A. Glennon, Ph.D. Virginia Commonwealth University NIDA Research Monograph 146 1994 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service National Institutes of Health National Institute on Drug Abuse 5600 Fishers Lane Rockville, MD 20857 ACKNOWLEDGEMENT This monograph is based on the papers from a technical review on “Hallucinogens: An Update” held on July 13-14, 1992. The review meeting was sponsored by the National Institute on Drug Abuse. COPYRIGHT STATUS The National Institute on Drug Abuse has obtained permission from the copyright holders to reproduce certain previously published material as noted in the text. Further reproduction of this copyrighted material is permitted only as part of a reprinting of the entire publication or chapter. For any other use, the copyright holder’s permission is required. All other material in this volume except quoted passages from copyrighted sources is in the public domain and may be used or reproduced without permission from the Institute or the authors. Citation of the source is appreciated. Opinions expressed in this volume are those of the authors and do not necessarily reflect the opinions or official policy of the National Institute on Drug Abuse or any other part of the U.S. Department of Health and Human Services. The U.S. Government does not endorse or favor any specific commercial product or company.
    [Show full text]
  • Clinical Manual of Geriatric Psychopharmacology This Page Intentionally Left Blank Clinical Manual of Geriatric Psychopharmacology
    Clinical Manual of Geriatric Psychopharmacology This page intentionally left blank Clinical Manual of Geriatric Psychopharmacology Sandra A. Jacobson, M.D. Assistant Professor, Department of Psychiatry and Human Behavior, Brown Medical School, Providence, Rhode Island Ronald W. Pies, M.D. Clinical Professor of Psychiatry, Tufts University School of Medicine, Boston, Massachusetts Ira R. Katz, M.D. Professor of Psychiatry and Director, Section of Geriatric Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania Washington, DC London, England Note: The authors have worked to ensure that all information in this book is accurate at the time of publication and consistent with general psychiatric and medical standards, and that information concerning drug dosages, schedules, and routes of administration is accurate at the time of publication and consistent with standards set by the U.S. Food and Drug Administration and the general medical community. As medical research and practice continue to advance, however, therapeutic standards may change. Moreover, specific situations may require a specific therapeutic response not included in this book. For these reasons and because human and mechanical errors sometimes occur, we recommend that readers follow the advice of physicians directly involved in their care or the care of a member of their family. Books published by American Psychiatric Publishing, Inc., represent the views and opinions of the individual authors and do not necessarily represent the policies and opinions of APPI or the American Psychiatric Association. Copyright © 2007 American Psychiatric Publishing, Inc. ALL RIGHTS RESERVED Manufactured in the United States of America on acid-free paper 11 10 09 08 07 5 4 3 2 1 First Edition Typeset in Adobe’s Formata and AGaramond.
    [Show full text]
  • EUROPEAN PHARMACOPOEIA 10.0 Index 1. General Notices
    EUROPEAN PHARMACOPOEIA 10.0 Index 1. General notices......................................................................... 3 2.2.66. Detection and measurement of radioactivity........... 119 2.1. Apparatus ............................................................................. 15 2.2.7. Optical rotation................................................................ 26 2.1.1. Droppers ........................................................................... 15 2.2.8. Viscosity ............................................................................ 27 2.1.2. Comparative table of porosity of sintered-glass filters.. 15 2.2.9. Capillary viscometer method ......................................... 27 2.1.3. Ultraviolet ray lamps for analytical purposes............... 15 2.3. Identification...................................................................... 129 2.1.4. Sieves ................................................................................. 16 2.3.1. Identification reactions of ions and functional 2.1.5. Tubes for comparative tests ............................................ 17 groups ...................................................................................... 129 2.1.6. Gas detector tubes............................................................ 17 2.3.2. Identification of fatty oils by thin-layer 2.2. Physical and physico-chemical methods.......................... 21 chromatography...................................................................... 132 2.2.1. Clarity and degree of opalescence of
    [Show full text]
  • α2-Adrenoceptor and 5-Ht3 Serotonin Receptor
    Virginia Commonwealth University VCU Scholars Compass Theses and Dissertations Graduate School 2012 α2-ADRENOCEPTOR AND 5-HT3 SEROTONIN RECEPTOR LIGANDS AS POTENTIAL ANALGESIC ADJUVANTS Genevieve Alley Virginia Commonwealth University Follow this and additional works at: https://scholarscompass.vcu.edu/etd Part of the Pharmacy and Pharmaceutical Sciences Commons © The Author Downloaded from https://scholarscompass.vcu.edu/etd/2867 This Dissertation is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It has been accepted for inclusion in Theses and Dissertations by an authorized administrator of VCU Scholars Compass. For more information, please contact [email protected]. © Genevieve Sirles Alley 2012 All Rights Reserved i α2-ADRENOCEPTOR AND 5-HT3 SEROTONIN RECEPTOR LIGANDS AS POTENTIAL ANALGESIC ADJUVANTS A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy at Virginia Commonwealth University. by Genevieve Sirles Alley Bachelor of Science in Biology, Virginia Commonwealth University 2005 Director: Małgorzata Dukat, Ph.D. Associate Professor, Department of Medicinal Chemistry Virginia Commonwealth University Richmond, Virginia August 2012 ii ACKNOWLEDGMENT First, I would like to thank Dr. Małgorzata Dukat for her continued assistance and advice throughout my studies. This guidance has helped me better understand and appreciate medicinal chemistry. Also, a special thanks is given to both Dr. Dukat and Dr. Richard A. Glennon for their constant quizzing during group meetings, which not only helped me recongnize what I did not already understand, but also, improved my ability to devise potential solutions for future research problems. Furthermore, I could not have successfully completed this dissertation work without the help of Dr.
    [Show full text]